Investigational melanoma vaccine targeting neoantigens and shared antigens with CD40 activation and TLR agonists
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Investigational melanoma vaccine targeting neoantigens and shared antigens with CD40 activation and TLR agonists, covering 2024-07-16 to 2024-07-16. Get the full timeline:
Most recent: Clinical Trial Update: Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) [Phase 1, Phase 2]